-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18

Benzinga·03/27/2026 12:33:48
Listen to the news
Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.